Trials / Recruiting
RecruitingNCT06668792
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCD-248 | subcutaneously |
Timeline
- Start date
- 2024-12-26
- Primary completion
- 2026-02-01
- Completion
- 2028-07-01
- First posted
- 2024-10-31
- Last updated
- 2025-02-04
Locations
20 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT06668792. Inclusion in this directory is not an endorsement.